For more information on presentations, panel discussions, round tables and workshops, please see the event guide.

7:30 am Registration, Coffee & Networking

8:20 am Chair’s Opening Remarks

  • Anderson Clark Director, Translational In Vivo Pharmacology, EMD Serono Research & Development Institute

8:30 am Local Immunotherapy with Cytokine mRNA Mixture Promotes Potent Anti-Tumor Immunity & Tumor Eradication Across Multiple Preclinical Tumor Models

Synopsis

  • Anti-tumor activity of intratumoral cytokine mRNA therapy in 20 syngeneic mouse models with “cold” and “hot” immune phenotypes
  • Immune mediated mechanism of action of local mRNA therapy in B16F10 tumor model with “cold” immune phenotype

The Changing Expectations of Model Requirements

8:55 am Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery

9:20 am Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses

  • Mike Brehm Professor , University of Massachusetts

9:45 am An overview of the JAX Human PDX Tumor Repository

  • Rick Huntress Director of Commercial Business Development , The Jackson Laboratory

10:10 am Panel Discussion – The Changing Expectations of Model Requirements

  • Davy Ouyang Executive Director , Crown Bioscience
  • Mike Brehm Professor , University of Massachusetts
  • Rick Huntress Director of Commercial Business Development , The Jackson Laboratory

10:30 am Speed Networking

11:00 am Morning Refreshments

Advances in Preclinical and Translational Imaging

Chaired by: Esmaiel Jabbari Professor, University of South Carolina

 

11.30 How Regeneron Uses Micro-Ultrasound Technology to Further Understanding of Anti-VEGF Therapy Effects in Preclinical Tumor Models

Alexander Adler, Scientist, Regeneron


11.45 Characterization of Mouse Syngeneic Tumor Models Using Multiplex T Cell Panel

Omid Ghasemi, Scientist I, Imaging, Takeda


12.10 Using 3D Imaging & AI to Advance Preclinical Cancer Research

Juan Delgado, Lead Data Scientist, Fuel3D


12.25 Using Clearing-Enhanced 3D (Ce3D) to Dissect Tumor Immune Microenvironment in Genetically Egineered Mouse Models

Chen Zhao, Clinical Fellow, National Institutes of Health


12.50 Q&A Panel - Advances in Preclinical & Translational Imaging

Omid Ghasemi, Scientist I, Imaging, Takeda
Chen Zhao, Clinical Fellow, National Institutes of Health
Alexander Adler, Scientist, Regeneron
Juan Delgado, Lead Data Scientist, Fuel3D

Advancing Biologic Therapeutics

1:10 pm Lunch

Engineering & Targeting the Microenvironment

2.10 Applications of An In-Vitro Multi-Cell Model of the Tumor Microenvironment

Daniel Gioeli, Associate Professor,  University of Virginia


2.35 Attention to Metastasis: Understanding Importance of Tumor Microenvironment In Immunotherapy Development

Jenni Bernoulli, COO, Pharmatest Services


2.50 Targeting Immunosuppression in the Tumor Microenvironment – Modelling Tumor-Immune Interactions In Vitro

Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis


3.15 Q&A Panel – Engineering & Targeting The Microenvironment

Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis
Daniel Gioeli, Associate Professor,  University of Virginia
Jenni Beroulli, COO,  Pharmatest Services

Novel Models for Novel Targets

3:30 pm Afternoon Refreshments

Modelling Cancer Drug Resistance

4:15 pm PDX-Derived 3D Models to Study Drug Resistance and Novel Combinations

  • Haluk Yuzugullu In Vivo Lead, Associate Principal Scientist, IMED , AstraZeneca

4:40 pm Translation of Preclinical Tumor Modeling of EZH2 Inhibition to Clinical Proof of Concept

5:05 pm Q&A – Modelling Cancer Drug Resistance

  • Neil Michaud Director, Translational Medicine , EpiZyme
  • Haluk Yuzugullu In Vivo Lead, Associate Principal Scientist, IMED , AstraZeneca

5:30 pm Close of Conference Day One

  • Anderson Clark Director, Translational In Vivo Pharmacology, EMD Serono Research & Development Institute

5:40 pm Evening Drinks Reception & Poster Session Hosted by Crown Bioscience